Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Market Cap	456.07M
Revenue (ttm)	4.58M
Net Income (ttm)	-168.03M
Shares Out	46.54M
EPS (ttm)	-4.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,495
Average Volume	60,949
Open	9.69
Previous Close	9.60
Day's Range	9.50 - 9.80
52-Week Range	19.00 - 40.00
Beta	n/a
RSI	37.26
Earnings Date	Apr 17, 2025

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases. Its lead product is linaprazan glurate for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer bacteria Helicobacter pylori (H. pylori). The company was founded in 2014 and is based in Stockholm, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 18
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CINPHA

Financial Performance

In 2024, Cinclus Pharma Holding AB's revenue was 4.58 million, a decrease of -23.14% compared to the previous year's 5.96 million. Losses were -168.03 million, -21.89% less than in 2023.